Atea Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Atea Pharmaceuticals

10/05/2022 14:00

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 51 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 58 cents per share.
    * Reported revenue was zero​;  analysts expected $3.33
million. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 51 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Atea Pharmaceuticals Inc shares had fallen by 26.2% this
quarter and lost 40.4% so far this year.
    * The company reported a quarterly loss of $42.08 million.
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $7.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated May 10 at 01:00 p.m.  ​All
figures in US dollars unless otherwise stated